nach oben

Erschienen in:

01.05.2012 | Original Article

Efficacy of prophylactic single-dose therapy using fluoroquinolone for prostate brachytherapy

verfasst von: Takeo Nomura, Kenichi Hirai, Mutsushi Yamasaki, Toru Inoue, Mika Takahashi, Takayuki Kawashima, Fuminori Sato, Hiromitsu Mimata

Erschienen in: Japanese Journal of Radiology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

There is little definitive evidence to guide the use of prophylactic antibiotics for prostate brachytherapy. The purpose of this study is to evaluate the incidence of postimplant infections in patients who receive antimicrobial prophylaxis with pazufloxacin (PZFX).

Materials and methods

A total of 84 patients who underwent prostate brachytherapy received a single intravenous dose of PZFX at 500 mg perioperatively for 1 day. No postimplant antibiotic medication was prescribed. Urinalysis, plasma white blood cell (WBC) count, and C reactive protein (CRP) levels were evaluated before the implantation, on the day after implantation, and on the 7th and 28th days after brachytherapy.

Results

None of the 84 patients (0.0%) developed a symptomatic urinary tract infection or had febrile infectious complications after brachytherapy. There were statistically significant elevations in the levels of erythrocytes, leukocytes, bacteria in urine, plasma WBC and CRP postoperatively, but these values did not exceed the normal range or were only slightly elevated on the day after brachytherapy (day 1) and on day 7. All laboratory examinations had returned to the normal range on day 28.

Conclusion

Single-dose therapy with fluoroquinolone helps to prevent infections after prostate brachytherapy.

Lin K, Lipsitz R, Miller T, Janakiraman S, U.S. Preventive Services Task Force. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149:192–9.PubMed

Porter AT, Blasko JC, Grimm PD, Reddy SM, Ragde H. Brachytherapy for prostate cancer. CA Cancer J Clin. 1995;45:165–78.PubMedCrossRef

Merrick GS, Wallner KE, Butler WM. Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland. J Urol. 2003;169:1643–52.PubMedCrossRef

Hoffelt SC, Wallner K, Merrick G. Epididymitis after prostate brachytherapy. Urology. 2004;63:293–6.PubMedCrossRef

Rivera R, Barboglio PG, Hellinger M, Gousse AE. Staging rectourinary fistulas to guide surgical treatment. J Urol. 2007;177:586–8.PubMedCrossRef

Lesperance RN, Kjorstadt RJ, Halligan JB, Steele SR. Colorectal complications of external beam radiation versus brachytherapy for prostate cancer. Am J Surg. 2008;195:616–20.PubMedCrossRef

Gilmore PE, Baird AD, Javle PM. Prostate abscess: a rare complication of brachytherapy for prostate cancer. Ann R Coll Surg Engl. 2009;91:12–4.CrossRef

Griffith BC, Morey AF, Al-Khan MM, Canby-Hagino E, Foley JP, Rozanski TA. Single dose levofloxacin prophylaxis for prostate biopsy in patients at low risk. J Urol. 2002;168:1021–3.PubMedCrossRef

Cormio L, Berardi B, Callea A, Fiorentino N, Sblendorio D, Zizzi V, et al. Antimicrobial prophylaxis for transrectal prostatic biopsy: a prospective study of ciprofloxacin vs piperacillin/tazobactam. BJU Int. 2002;90:700–2.PubMedCrossRef

10.

Matsumoto T, Kiyota H, Matsukawa M, Yasuda M, Arakawa S, Monden K, et al. Japanese guidelines for prevention of perioperative infections in urological field. Int J Urol. 2007;14:890–909.PubMedCrossRef

11.

Rietbergen JB, Kruger AE, Kranse R, Schröder FH. Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program. Urology. 1997;49:875–80.PubMedCrossRef

12.

Zaytoun OM, Anil T, Moussa AS, Jianbo L, Fareed K, Jones JS. Morbidity of prostate biopsy after simplified versus complex preparation protocols: assessment of risk factors. Urology. 2011;77:910–4.PubMedCrossRef

13.

Desmond PM, Clark J, Thompson IM, Zeidman EJ, Mueller EJ. Morbidity with contemporary prostate biopsy. J Urol. 1993;150:1425–6.PubMed

14.

Thompson PM, Pryor JP, Williams JP, Eyers DE, Dulake C, Scully MF, et al. The problem of infection after prostatic biopsy: the case for the transperineal approach. Br J Urol. 1982;54:736–40.PubMedCrossRef

15.

Onder AU, Yaycioglu O, Ataus S, Gul U, Demirkesen O, Yalcin V, et al. Transition zone biopsy and prediction of extraprostatic extension at radical prostatectomy. Int J Urol. 2003;10:302–8.PubMedCrossRef

16.

Packer MG, Russo P, Fair WR. Prophylactic antibiotics and Foley catheter use in transperineal needle biopsy of the prostate. J Urol. 1984;131:687–9.PubMed

17.

Bice WS Jr, Prestidge BR, Prete JJ, Dubois DF. Clinical impact of implementing the recommendations of AAPM Task Group 43 on permanent prostate brachytherapy using ¹²⁵I. American Association of Physicists in Medicine. Int J Radiat Oncol Biol Phys. 1998;40:1237–41.PubMedCrossRef

18.

Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practice Advisory Committee. Infect Control Hosp Epidemiol. 1999;20:250–78.PubMedCrossRef

19.

Naber KG, Bergman B, Bishop MC, Bjerklund-Johansen TE, Botto H, Lobel B, et al. EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). Eur Urol. 2001;40:576–88.PubMedCrossRef

20.

Wallner K, Roy J, Harrison L. Low risk of perioperative infection without prophylactic antibiotics for transperineal prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1996;36:681–3.PubMedCrossRef

21.

Dicker AP, Figura AT, Waterman FM, Valicenti RK, Strup SE, Gomella LG. Is there a role for antibiotic prophylaxis in transperineal interstitial permanent prostate brachytherapy? Tech Urol. 2000;6:104–8.PubMed

22.

Lugg J, Lettieri J, Stass H, Agarwal V. Determination of the concentration of ciprofloxacin in prostate tissue following administration of a single, 1000 mg, extended-release dose. J Chemother. 2008;20:213–8.PubMed

23.

Fukuoka Y, Ikeda Y, Yamashiro Y, Takahata M, Todo Y, Narita H. In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative. Antimicrob Agents Chemother. 1993;37:384–92.PubMed

24.

Shigemura K, Yasufuku T, Yamashita M, Arakawa S, Fujisawa M. Prophylactic use of isepamicin and levofloxacin for transrectal prostate biopsy: a retrospective single center study. Int J Urol. 2009;16:723–5.PubMedCrossRef

Titel: Efficacy of prophylactic single-dose therapy using fluoroquinolone for prostate brachytherapy
verfasst von: Takeo Nomura
Kenichi Hirai
Mutsushi Yamasaki
Toru Inoue
Mika Takahashi
Takayuki Kawashima
Fuminori Sato
Hiromitsu Mimata
Publikationsdatum: 01.05.2012
Verlag: Springer Japan
Erschienen in: Japanese Journal of Radiology / Ausgabe 4/2012
Print ISSN: 1867-1071
Elektronische ISSN: 1867-108X
DOI: https://doi.org/10.1007/s11604-012-0053-z

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Efficacy of prophylactic single-dose therapy using fluoroquinolone for prostate brachytherapy